Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CTD Holdings to Present at WORLD Symposium on Lysosomal Storage Diseases | ||
By: Nasdaq / GlobeNewswire - 12 Dec 2018 | Back to overview list |
|
ALACHUA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced acceptance of two presentations at the annual WORLD (We’re Organizing Research on Lysosomal Diseases) Symposium to be held February 4 – 8, 2019 in Orlando, Florida. The Symposium is designed for basic, translational and clinical researchers, patient advocacy groups, clinicians and others interested in learning more about the latest discoveries related to lysosomal diseases and the clinical investigation of these advances. WORLD attracts participants from across the globe. “CTD is pleased to have the opportunity to discuss our latest clinical findings with scientific and clinical colleagues and advocates for Niemann-Pick Disease Type C,” said CTD Chairman and CEO, N. Scott Fine. “This gathering is a significant opportunity for us to share information and to engage with all stakeholders working to end suffering from this tragic disease.” Niemann-Pick disease type C (NPC) is a rare and fatal genetic disease characterized by the accumulation of cholesterol in every cell in the body. There is no cure. CTD will present two posters as part of the Late-Breaker session: Wednesday, February 6, 2019 The poster titles are: “Initial findings from a Phase I clinical trial using hydroxypropyl beta cyclodextrin intravenously in Niemann-Pick type C patients” “Initial safety and efficacy findings for a Phase I/II trial of hydroxypropyl beta cyclodextrins administered intravenously in patient with Niemann-Pick Type C disease.” The presentations will be made by Dr. Caroline Hastings, Principal Investigator for the Phase I study at the at UCSF Benioff Children’s Hospital Oakland, CA site and Dr. Reena Sharma, Coordinating Investigator for the Phase I/II EU/Israel study and Principal Investigator at the UK site at Salford Royal Foundation Trust, Salford, joined by Dr. Orna Staretz-Chacham, Principal Investigator for the Soroka Medical Center site in BeerSheva, Israel,and Dr. Hrynkow. CTD Chairman and CEO will attend WORLD and will join the presentations. About CTD Holdings: Safe Harbor Statement: Investor/Media Contact: Thomas Mulligan |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |